Eli Lilly bets $409M for AI-focused drug discovery
by
Contributor since / Followers
Contributor since / Followers
4 days ago
lcodacci Genetic Leap, a company focused on AI-driven drug discovery, announced Thursday a research collaboration
LLY
Eli Lilly marks late-stage trial win for once weekly insulin
by
Contributor since / Followers
Contributor since / Followers
4 days ago
JHVEPhoto/iStock Editorial via Getty Images Eli Lilly (NYSE:LLY) on Thursday announced that its QWINT-1 and
QIAGEN, Lilly to develop Alzheimer’s risk detection test
by
Contributor since / Followers
Contributor since / Followers
5 days ago
jetcityimage/iStock Editorial via Getty Images QIAGEN (NYSE:QGEN) has entered into a collaboration with Eli Lilly
Inspire Medical gains on GLP-1 prospects
by
Contributor since / Followers
Contributor since / Followers
5 days ago
spawns Inspire Medical Systems (NYSE:INSP) traded higher on Wednesday after MedTech’s CEO argued that the
UK regulators find no link between certain GLP-1 drugs, suicidal thoughts
by
Contributor since / Followers
Contributor since / Followers
5 days ago
Peter Hansen UK regulators have determined there is no causal link between weight-loss and diabetes
Eli Lilly’s quest for obesity drugs leads to $1B bet on dark genome
by
Contributor since / Followers
Contributor since / Followers
5 days ago
jetcityimage/iStock Editorial via Getty Images Eli Lilly (NYSE:LLY) has inked a deal worth up to
Novartis expands U.S. radiopharma production amid rising competition
by
Contributor since / Followers
Contributor since / Followers
5 days ago
TBE/iStock Editorial via Getty Images Novartis (NYSE:NVS) on Wednesday announced the construction of two new
Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
by Manika Premsingh
Contributor since 2022 / 2937 Followers
Contributor since 2022 / 2937 Followers
5 days ago
Summary: Eli Lilly’s weight loss treatment Zepbound might be a blockbuster in the making, but
Eli Lilly inks licensing deal to expand Olumiant access in Africa
by
Contributor since / Followers
Contributor since / Followers
5 days ago
jetcityimage/iStock Editorial via Getty Images Eli Lilly (NYSE:LLY) announced on Wednesday an agreement with Egypt-based
Novo Nordisk warns of continued Ozempic shortage in Q4
by
Contributor since / Followers
Contributor since / Followers
6 days ago
hapabapa/iStock Editorial via Getty Images Novo Nordisk (NVO) has said in a note published by